Altogether, our study demonstrated that BYF reduced renal fibrosis and inflammation by TLR4-mediated NF-κb signaling pathway suppression, which may be a key mechanism of its therapeutic effect on CKD. The gene discussed is NFKB1; the disease is renal fibrosis.